Is this pharma stock about to bounce back in 2021?

Is the demand for elective surgeries about to explode? Zaven Boyrazian analyses a pharma stock perfectly positioned to take advantage of the growing demand.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

The pandemic has created a challenging environment for pharma stocks like Advanced Medical Solutions (LSE:AMS).  Its performance in 2020 is best described as lacklustre, but not entirely unexpected.

The business is a developer and manufacturer of surgical and wound care products. These range from tissue adhesives to wound dressings sold under multiple globally recognised brands. With lockdowns keeping people at home, A&E visits have dropped by almost half. Furthermore, with hospitals overwhelmed by Covid-19 patients, many elective surgeries have been delayed by a similar rate.

Combined, this had led to a significant decline in product sales. But now that the vaccine rollout is underway, is the tide about to change? Is this pharma stock about to make a comeback in 2021? And should I consider adding it to my portfolio? 

A pioneer in wound care

AMS has been around since the early 1990s. It was initially a research and development firm. But skip forward a few decades and a couple acquisitions, and the pharma stock has become a leader within its market space.

The business can be broken up into two units. Unit one is called Surgical. It sells AMS branded products to medical centres – such as hospitals – directly or through third-party distributors. The second unit is called Woundcare. This division develops and supplies a wide range of products to its business partners, who subsequently use them to create their own branded products.

Both segments are responsible for generating a roughly even split of total revenue. However, the Surgical unit appears to be significantly more profitable, with an operating margin of 34% in 2019.

As previously stated, Covid-19 has had a major impact on this stock. While its manufacturing facilities remained in operation throughout 2020, general demand for the firm’s products fell sharply. As a result, forecast revenue for 2020 is expected to be around 20% lower than in 2019.

However, the catalyst behind this poor performance looks only temporary to me. And with Covid-19 slowly coming under control, I believe that demand can return and even grow in the latter part of 2021. But as always, there are plenty of challenges and risks ahead.

A fiercely competitive market

Wound care and surgical are highly competitive spaces. While regulators make it difficult for new entrants, the number of global competitors for the company continues to rise.

As such, the need to continually innovate and expand its intellectual property portfolio is exceptionally high. But this might begin straining the company’s financials.

Fortunately, there’s a large proportion of cash on the balance sheet that has proven vital to continue funding its R&D department throughout the pandemic. However, should the business make another acquisition, this cash balance may no longer be available to rely on if another similar event were to occur.

Is this pharma stock about to create explosive returns

Is the pharma stock on my buy list?

AMS looks perfectly positioned for a rebound in my eyes. Assuming that demand returns to pre-Covid levels later this year, the current stock price seems relatively low. The fierce competition will continue to be an ever-present threat, but the potential reward might just outweigh the risk.

Therefore I think the stock could be a fantastic opportunity for value investors, and perhaps even my portfolio as well.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian does not own shares in Advanced Medical Solutions. The Motley Fool UK has recommended Advanced Medical Solutions. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

4 Teslas in a parking lot at a charger station
Investing Articles

The Tesla share price slips further — how much would £10k invested at the start of the year be worth now?

The Tesla share price remains under pressure, with risks mounting from multiple directions. Here’s what a £10,000 investment would be…

Read more »

British pound data
Investing Articles

The Ocado share price is a sea of red! Time to cut my losses?

Every time Harvey Jones checks out the Ocado share price, he sees red. Will it ever stop falling and leaving…

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

Over the next 5 years, I think these S&P 500 stocks will make me more money than a global index fund can

Edward Sheldon believes that these two high-quality S&P 500 growth stocks have the potential to beat the market over the…

Read more »

British union jack flag and Parliament house at city of Westminster in the background
Investing Articles

Over the last 2 years, this investment trust has doubled the FTSE 100 index’s return

Here are three key reasons why our writer reckons this high-quality investment trust from the FTSE 100 index is worth…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

Keep an eye on this FTSE 100 stock in the week ahead

The last time Bunzl issued a trading update, the stock fell 25%. So could the FTSE 100 stock be set…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

This FTSE 100 bank is up 60% in year but still cheap with a P/E of just 9!

Harvey Jones has overlooked this FTSE 100 bank, until today. It's been bombing along yet still looks decent value. But…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

Stocks and Shares ISA in the red? Here’s how to try and get back on track

Despite upward momentum in the stock market, not every Stocks and Shares ISA’s in the black. Zaven Boyrazian explores strategies…

Read more »

Array of piggy banks in saturated colours on high colour contrast background
Investing Articles

Could missing this dividend stock in 2025 be a costly mistake?

Before 2022, this dividend stock was beating the market by more than four times! Could it be about to do…

Read more »